| Size | Price | Stock | Qty |
|---|---|---|---|
| 1mg |
|
||
| 5mg |
|
||
| 10mg |
|
||
| 25mg |
|
||
| 50mg |
|
||
| 100mg | |||
| Other Sizes |
| Targets |
VU6015929 targets discoidin domain receptor 1 (DDR1) and discoidin domain receptor 2 (DDR2), which are collagen receptor tyrosine kinases. It potently inhibits collagen-induced DDR1 activation and collagen-IV production, suggesting DDR1 inhibition as a target for antifibrotic therapy. The compound is orally active and selective for DDR1/2.
|
|---|---|
| ln Vitro |
The HEK293-DDR1b cells treated with VU6015929 (Compound 7e; 4-100 nM; 24 hours) showed a dose-dependent inhibition of collagen I-induced DDR1 phosphorylation. According to a study of the phosphorylated DDR1/total DDR1 ratio, VU6015929's IC50 is 0.7078 nM [1].
In vitro, VU6015929 inhibits DDR1 and DDR2 with IC50 values of 4.67 nM and 7.39 nM, respectively. In HEK293-DDR1b cells, it inhibits collagen I-stimulated DDR1 phosphorylation in a dose-dependent manner with subnanomolar potency (IC50 = 0.71 nM). The compound potently blocks collagen-IV production. |
| ln Vivo |
VU6015929 (Compound 7e) was further examined in a rat IV (0.5 mg/kg)/PO (3 mg/kg) PK trial in 10% EtOH/40% PEG400/50% saline vehicle. VU6015929 demonstrates good in vitro:in vivo correlation (IVIC), has moderate in vivo clearance (CLp = 34.2 mL/min/kg), a half-life of approximately 3 hours, and a moderate volume of distribution at steady state (Vss = 4.3 L) /kg) and 12.5% oral bioavailability with a quick Tmax (0.75 hours) [1].
In vivo activity data for VU6015929 are not extensively detailed in the available sources. Pharmacokinetic studies in rats show moderate clearance, a ~3 h half-life, moderate distribution volume, and rapid absorption (Tmax = 0.75 h), though with limited oral bioavailability (12.5%). The compound is orally active. |
| Enzyme Assay |
The in vitro enzyme assay for VU6015929 involves measuring the inhibition of DDR1 and DDR2 kinase activity. Recombinant kinases are incubated with substrates and ATP in the presence of varying compound concentrations. The IC50 values are determined by quantifying the reduction in substrate phosphorylation using techniques such as radioactive or fluorescence-based assays.
|
| Cell Assay |
Western Blot Analysis[1]
Cell Types: HEK293-DDR1b Cell Tested Concentrations: 4 nM, 20 nM, 100 nM Incubation Duration: 24 hrs (hours) Experimental Results: Inhibits collagen I-induced DDR1 phosphorylation in a dose-dependent manner. Dramatically inhibits the production of type IV collagen. Cellular assays are performed using HEK293-DDR1b cells. Cells are treated with VU6015929 and stimulated with collagen I. DDR1 phosphorylation is measured by Western blot analysis using phospho-specific antibodies. The compound's potency in blocking DDR1 activation is assessed from dose-response curves. |
| Animal Protocol |
In vivo animal studies for VU6015929 are not detailed in the available sources. Pharmacokinetic studies have been conducted in rats, with the compound showing rapid absorption and moderate clearance. Specific efficacy studies in animal models of fibrosis or cancer are not described.
|
| ADME/Pharmacokinetics |
VU6015929 has moderate clearance, a ~3 h half-life, and moderate distribution volume in rats. It shows rapid absorption with a Tmax of 0.75 h but limited oral bioavailability (12.5%). The compound is orally active and suitable for in vivo studies.
|
| Toxicity/Toxicokinetics |
Toxicity data for VU6015929 are not reported in the available sources. As an investigational compound, it is used for research purposes only. Specific toxicological profiles are not available.
|
| References | |
| Additional Infomation |
VU6015929 is a research tool for studying DDR1/2 signaling in fibrosis, cancer, and collagen-related pathologies. It is a potent and selective inhibitor with oral activity. The compound is available from chemical suppliers for research use only.
|
| Molecular Formula |
C24H19F4N5O2
|
|---|---|
| Molecular Weight |
485.4336
|
| Exact Mass |
485.147
|
| CAS # |
2442597-56-8
|
| PubChem CID |
145925694
|
| Appearance |
White to yellow solid powder
|
| Density |
1.37±0.1 g/cm3(Predicted)
|
| Boiling Point |
553.3±50.0 °C(Predicted)
|
| LogP |
4.4
|
| Hydrogen Bond Donor Count |
2
|
| Hydrogen Bond Acceptor Count |
9
|
| Rotatable Bond Count |
7
|
| Heavy Atom Count |
35
|
| Complexity |
699
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CN1C=CC(=N1)C2=CN=CC(=C2)CNC3=C(C=CC(=C3)C(=O)NC4=CC(=CC=C4)OC(F)(F)F)F
|
| InChi Key |
IZKVIUJIUTXIRH-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C24H19F4N5O2/c1-33-8-7-21(32-33)17-9-15(12-29-14-17)13-30-22-10-16(5-6-20(22)25)23(34)31-18-3-2-4-19(11-18)35-24(26,27)28/h2-12,14,30H,13H2,1H3,(H,31,34)
|
| Chemical Name |
4-fluoro-3-[[5-(1-methylpyrazol-3-yl)pyridin-3-yl]methylamino]-N-[3-(trifluoromethoxy)phenyl]benzamide
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
DMSO : ~250 mg/mL (~515.01 mM)
|
|---|---|
| Solubility (In Vivo) |
Solubility in Formulation 1: ≥ 2.08 mg/mL (4.28 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL. Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution. Solubility in Formulation 2: ≥ 2.08 mg/mL (4.28 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution. For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly. (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.0600 mL | 10.3001 mL | 20.6003 mL | |
| 5 mM | 0.4120 mL | 2.0600 mL | 4.1201 mL | |
| 10 mM | 0.2060 mL | 1.0300 mL | 2.0600 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
